公开(公告)号：US20200277299A1

公开(公告)日：2020-09-03

申请号：US16876621

申请日：2020-05-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20200237697A1

公开(公告)日：2020-07-30

申请号：US16606520

申请日：2018-04-18

Applicant: NEONC TECHNOLOGIES, INC.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/20 ,  A61K47/55 ,  A61K45/06 ,  A61K9/00 ,  A61K31/045

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20160332942A1

公开(公告)日：2016-11-17

申请号：US15220135

申请日：2016-07-26

Applicant: NEONC Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: C07C29/78 ,  C07C29/92

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20220363619A1

公开(公告)日：2022-11-17

申请号：US17749293

申请日：2022-05-20

Applicant: NEONC Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  A61K31/045 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20200078355A1

公开(公告)日：2020-03-12

申请号：US16384534

申请日：2019-04-15

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K47/54 ,  A61K9/00 ,  C07C33/14 ,  C07B59/00 ,  A61K31/4015 ,  A61K31/045 ,  A61K31/4188 ,  C07D487/04 ,  C07D231/12 ,  C07D207/26 ,  A61N5/10 ,  A61K45/06 ,  A61K31/415

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20190275031A1

公开(公告)日：2019-09-12

申请号：US16123729

申请日：2018-09-06

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K47/54 ,  A61K31/415 ,  A61K9/00 ,  C07C33/14 ,  A61K45/06 ,  C07B59/00 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/4188 ,  C07D487/04 ,  C07D231/12 ,  C07D207/26 ,  A61N5/10

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20170128578A1

公开(公告)日：2017-05-11

申请号：US15291847

申请日：2016-10-12

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A01N43/52 ,  A61K45/06 ,  C07D231/12 ,  C07D487/04 ,  A61K31/4015 ,  C07D207/26 ,  A61K31/415 ,  A61K31/495

CPC classification number: A61K31/495 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K45/06 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61N5/10 ,  C07B59/00 ,  C07B2200/05 ,  C07C33/14 ,  C07C2601/16 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20170119758A1

公开(公告)日：2017-05-04

申请号：US15408866

申请日：2017-01-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K9/00 ,  A61N5/10 ,  A61K45/06

CPC classification number: C07C33/14 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/495 ,  A61K45/06 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61N5/10 ,  C07B59/00 ,  C07B2200/05 ,  C07C2601/16 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene for sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.